GlassScriptPhysician profile
John M Dubaz
NPI 1437247350
$9,115.09
in general payments reported to CMS, 2019-2025
26 companies · $856 in 2025
The $856 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,180 · 2020: $278 · 2021: $414 · 2022: $773 · 2023: $797 · 2024: $816 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,469.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,992.99 | 2019-2025 | Penmenvy, Bexsero, Pediarix |
| Tris Pharma INC | $1,195.79 | 2019-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Corium, LLC | $612.76 | 2022-2025 | Azstarys, Azstarys |
| Kaleo, INC. | $441.35 | 2019-2024 | Auvi-Q |
| Cranial Technologies, INC | $248.87 | 2019-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $247.78 | 2019-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $196.66 | 2023-2025 | |
| Medtronic, INC. | $156.39 | 2025 | Endurant Iis |
| Sanofi Pasteur INC. | $150.67 | 2019-2025 | |
| Ironshore Pharmaceuticals INC. | $143.87 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $130.12 | 2025 | Neffy |
| Genzyme Corporation | $117.05 | 2021 | |
| Adlon Therapeutics L.P. | $114.14 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $81.06 | 2022-2024 | Strensiq |
| Genentech USA, INC. | $61.41 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $28.09 | 2025 | Neffy |
| Hologic Sales and Service, LLC | $24.74 | 2024 | Third Wave |
| Aimmune Therapeutics, INC. | $23.70 | 2022 | |
| Shire North American Group INC | $22.48 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.42 | 2025 | Ycanth |
| Seqirus USA INC | $20.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.87 | 2019 | |
| Photonicare INC | $18.87 | 2025 | Otosight Middle Ear Scope |
| Kowa Pharmaceuticals America, INC. | $16.95 | 2025 | Zoryve |
| Bavarian Nordic A/S | $14.04 | 2025 | Vivotif |
| Incyte Corporation | $12.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dubaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.